Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan

THE TREATMENT FOR RECURRENT FEMALE BREAST CANCER AFTER INITIAL ENDOCRINE THERAPY AMONG TAIWANESE POPULATION

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02924584

Enrollment

Registered

2016-10-05

Start date

2017-02-01

Completion date

2018-04-30

Last updated

2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ER/PR(+), Her2(-) Breast Cancer

Keywords

hormonal receptor positive, human epidermal growth factor receptor 2 negative, breast cancer, aromatse inhibitor, overall survival, prevalence

Brief summary

Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305 were registered as early breast cancer. With broadly application of aromatase inhibitors, hormonal-receptor-positive breast cancer patients can survive longer and longer. However, there is no prevalence of metastatic breast cancer can be available yet. NHIA database coverage is more than 90% population in Taiwan, thus it can be an appropriate surrogate of prevalence. In this retrospective database analysis, we will explore the real world experience on aromatase inhibitor use for breast cancer in Taiwan.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* hormonal receptor positive, human epidermal growth factor receptor 2 negative breast cancer

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
clinical use of aromatase inhibitors in breast cancer	base line, up to 60 months	duration of treatment

Secondary

Measure	Time frame	Description
prevalence	base line up to 60 months	The prevalence of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
dose exposure	base line, up to 60 months	The dosage pattern of breast cancer with positive hormonal receptors with routine practice in Taiwan.
overall survival	base line, up to 60 months	The overall survival of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.
treatment cost	base line, up to 60 months	The treatment cost of metastatic breast cancer with positive hormonal receptors with routine practice in Taiwan.

Countries

Taiwan

Outcome results